409 related articles for article (PubMed ID: 9819224)
1. Induction of topoisomerase II-mediated DNA cleavage by a protoberberine alkaloid, berberrubine.
Kim SA; Kwon Y; Kim JH; Muller MT; Chung IK
Biochemistry; 1998 Nov; 37(46):16316-24. PubMed ID: 9819224
[TBL] [Abstract][Full Text] [Related]
2. Covalent attachment of ethidium to DNA results in enhanced topoisomerase II-mediated DNA cleavage.
Marx G; Zhou H; Graves DE; Osheroff N
Biochemistry; 1997 Dec; 36(50):15884-91. PubMed ID: 9398321
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of DNA topoisomerase I and II isolated from the Coptis rhizomes.
Kobayashi Y; Yamashita Y; Fujii N; Takaboshi K; Kawakami T; Kawamura M; Mizukami T; Nakano H
Planta Med; 1995 Oct; 61(5):414-8. PubMed ID: 7480201
[TBL] [Abstract][Full Text] [Related]
4. The 9-position in berberine analogs is an important determinant of DNA topoisomerase II inhibition.
Krishnan P; Bastow KF
Anticancer Drug Des; 2000 Aug; 15(4):255-64. PubMed ID: 11200501
[TBL] [Abstract][Full Text] [Related]
5. Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs.
Elsea SH; Westergaard M; Burden DA; Lomenick JP; Osheroff N
Biochemistry; 1997 Mar; 36(10):2919-24. PubMed ID: 9062121
[TBL] [Abstract][Full Text] [Related]
6. Eukaryotic DNA topoisomerases mediated DNA cleavage induced by a new inhibitor: NSC 665517.
Gupta M; Abdel-Megeed M; Hoki Y; Kohlhagen G; Paull K; Pommier Y
Mol Pharmacol; 1995 Oct; 48(4):658-65. PubMed ID: 7476891
[TBL] [Abstract][Full Text] [Related]
7. Minor groove-directed and intercalative ligand-DNA interactions in the poisoning of human DNA topoisomerase I by protoberberine analogs.
Pilch DS; Yu C; Makhey D; LaVoie EJ; Srinivasan AR; Olson WK; Sauers RR; Breslauer KJ; Geacintov NE; Liu LF
Biochemistry; 1997 Oct; 36(41):12542-53. PubMed ID: 9376359
[TBL] [Abstract][Full Text] [Related]
8. Topoisomerase II-mediated DNA cleavage by amonafide and its structural analogs.
Hsiang YH; Jiang JB; Liu LF
Mol Pharmacol; 1989 Sep; 36(3):371-6. PubMed ID: 2550774
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the topoisomerase II-DNA cleavable complex by the ortho-quinone derivative of the antitumor drug etoposide (VP-16).
Gantchev TG; Hunting DJ
Biochem Biophys Res Commun; 1997 Aug; 237(1):24-7. PubMed ID: 9266822
[TBL] [Abstract][Full Text] [Related]
10. Topoisomerase II mediated DNA lesions induced by acridine-4-carboxamide and 2-(4-pyridyl)quinoline-8-carboxamide.
Woynarowski JM; McCarthy K; Reynolds B; Beerman TA; Denny WA
Anticancer Drug Des; 1994 Feb; 9(1):9-24. PubMed ID: 8141968
[TBL] [Abstract][Full Text] [Related]
11. Induction of a heat-stable topoisomerase II-DNA cleavable complex by nonintercalative terpenoides, terpentecin and clerocidin.
Kawada S; Yamashita Y; Fujii N; Nakano H
Cancer Res; 1991 Jun; 51(11):2922-5. PubMed ID: 1851667
[TBL] [Abstract][Full Text] [Related]
12. Induction of mammalian DNA topoisomerase II dependent DNA cleavage by antitumor antibiotic streptonigrin.
Yamashita Y; Kawada S; Fujii N; Nakano H
Cancer Res; 1990 Sep; 50(18):5841-4. PubMed ID: 2168283
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of DNA topoisomerase IIalpha in human colorectal carcinoma cells resistant to a protoberberine alkaloid, berberrubine.
Kang MR; Chung IK
Mol Pharmacol; 2002 Apr; 61(4):879-84. PubMed ID: 11901227
[TBL] [Abstract][Full Text] [Related]
14. Topoisomerase II is a cellular target for antiproliferative cobalt salicylaldoxime complex.
Jayaraju D; Gopal YN; Kondapi AK
Arch Biochem Biophys; 1999 Sep; 369(1):68-77. PubMed ID: 10462441
[TBL] [Abstract][Full Text] [Related]
15. Dependence of etoposide-induced cytotoxicity and topoisomerase II-mediated DNA strand breakage on the intracellular ionic environment.
Lawrence TS; Canman CE; Maybaum J; Davis MA
Cancer Res; 1989 Sep; 49(17):4775-9. PubMed ID: 2547516
[TBL] [Abstract][Full Text] [Related]
16. Sequence selectivity of topoisomerase II DNA cleavage stimulated by mitoxantrone derivatives: relationships to drug DNA binding and cellular effects.
De Isabella P; Capranico G; Palumbo M; Sissi C; Krapcho AP; Zunino F
Mol Pharmacol; 1993 May; 43(5):715-21. PubMed ID: 8388987
[TBL] [Abstract][Full Text] [Related]
17. Antitumor quinolones with mammalian topoisomerase II mediated DNA cleavage activity.
Yamashita Y; Ashizawa T; Morimoto M; Hosomi J; Nakano H
Cancer Res; 1992 May; 52(10):2818-22. PubMed ID: 1316228
[TBL] [Abstract][Full Text] [Related]
18. [Poisons of DNA topoisomerases I and II].
Charcosset JY; Soues S; Laval F
Bull Cancer; 1993 Nov; 80(11):923-54. PubMed ID: 8081034
[TBL] [Abstract][Full Text] [Related]
19. Analysis of eukaryotic topoisomerase II cleavage sites in the presence of the quinolone CP-115,953 reveals drug-dependent and -independent recognition elements.
Spitzner JR; Chung IK; Gootz TD; McGuirk PR; Muller MT
Mol Pharmacol; 1995 Aug; 48(2):238-49. PubMed ID: 7651357
[TBL] [Abstract][Full Text] [Related]
20. Selective inhibition of topoisomerase II by ICRF-193 does not support a role for topoisomerase II activity in the fragmentation of chromatin during apoptosis of human leukemia cells.
Beere HM; Chresta CM; Hickman JA
Mol Pharmacol; 1996 May; 49(5):842-51. PubMed ID: 8622634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
